Advanced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency

Dr. Jesus G. Berdeja

Hematology Oncology | Hematology | Oncology
Select Physical Therapy Holdings Inc
9040 Carothers Pkwy, 
Franklin, TN 
Accepting New Patients
Offers Telehealth
26 Years of Experience
Advanced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
Select Physical Therapy Holdings Inc
9040 Carothers Pkwy, 
Franklin, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jesus Berdeja is a Hematologist Oncology specialist and a Hematologist in Franklin, Tennessee. Dr. Berdeja has been practicing medicine for over 26 years and is rated as an Advanced provider by MediFind in the treatment of Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Berdeja is currently accepting new patients.

His clinical research consists of co-authoring 112 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in TN
Hospital Affiliations
Tristar Centennial Medical Center
Ascension Saint Thomas Hospital
Languages Spoken
English
French
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

SELECT PHYSICAL THERAPY HOLDINGS INC
9040 Carothers Pkwy, Franklin, TN 37067
Other Locations
TENNESSEE ONCOLOGY PLLC
143 Prospect Hl, Nashville, TN 37205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma
A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2025
Intervention Type: Biological, Drug, Other, Procedure
Study Drugs: Daratumumab, Melphalan
Study Phase: Phase 2
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 3
Phase 2 Study of Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Phase 2 Study of Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Enrollment Status: Terminated
Publish Date: October 08, 2024
Intervention Type: Biological
Study Drug: Descartes 08
Study Phase: Phase 2
A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma
A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia
Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia
Enrollment Status: Completed
Publish Date: October 30, 2023
Intervention Type: Drug, Other
Study Drugs: Dexamethasone, Ixazomib Citrate, Pomalidomide
Study Phase: Phase 2
A Phase I Open Label First in Human Dose Escalation of the Immunoproteasome Inhibitor M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone in Participants With Relapsed Refractory Multiple Myeloma
A Phase I Open Label First in Human Dose Escalation of the Immunoproteasome Inhibitor M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone in Participants With Relapsed Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: March 24, 2023
Intervention Type: Drug
Study Drugs: M3258, Dexamethasone
Study Phase: Phase 1
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
Enrollment Status: Unknown
Publish Date: February 16, 2023
Intervention Type: Biological
Study Drug: CYNK-001
Study Phase: Phase 1
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
Phase I/Ib, Multi-center, Open-label, Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Relapsed and/or Refractory Multiple Myeloma
Phase I/Ib, Multi-center, Open-label, Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: February 09, 2022
Intervention Type: Drug
Study Phase: Phase 1
Phase 1 Study of Daratumumab When Given in Combination With Bortezomib, Dexamethasone, Doxil, and Lenalidomide in Patients With Plasma Cell Leukemia
Phase 1 Study of Daratumumab When Given in Combination With Bortezomib, Dexamethasone, Doxil, and Lenalidomide in Patients With Plasma Cell Leukemia
Enrollment Status: Withdrawn
Publish Date: December 19, 2018
Intervention Type: Drug, Biological
Study Phase: Phase 1
View 11 Less Clinical Trials

112 Total Publications

Operationalization and Use of Bispecific T-Cell-Engaging Antibodies in Community Practices: Multidisciplinary Perspectives on Developing Logistics and Workflow for Cytokine Release Syndrome Management.
Operationalization and Use of Bispecific T-Cell-Engaging Antibodies in Community Practices: Multidisciplinary Perspectives on Developing Logistics and Workflow for Cytokine Release Syndrome Management.
Journal: Journal of the advanced practitioner in oncology
Published: August 07, 2025
Similar Doctors
Advanced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
Dr. Varun C. Dhulipala
Hematology Oncology | Hematology
Advanced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
Dr. Varun C. Dhulipala
Hematology Oncology | Hematology

Tennessee Oncology PLLC

808 S James M Campbell Blvd, 
Columbia, TN 
 (28.7 miles away)
931-381-3872
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Varun Dhulipala is a Hematologist Oncology specialist and a Hematologist in Columbia, Tennessee. Dr. Dhulipala is rated as a Distinguished provider by MediFind in the treatment of Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency. His top areas of expertise are Paris-Trousseau Thrombocytopenia, RUNX1 Familial Platelet Disorder, Paget Disease of the Breast, and Large-Cell Immunoblastic Lymphoma. Dr. Dhulipala is currently accepting new patients.

Advanced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
Dr. Muhamed Baljevic
Hematology Oncology | Hematology | Oncology
Advanced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
Dr. Muhamed Baljevic
Hematology Oncology | Hematology | Oncology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (12.6 miles away)
615-322-3000
Languages Spoken:
English, Bosnian, Tibetan Standard
See accepted insurances
Accepting New Patients
Offers Telehealth

Muhamed Baljevic is a Hematologist Oncology specialist and a Hematologist in Nashville, Tennessee. Dr. Baljevic is rated as a Distinguished provider by MediFind in the treatment of Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Baljevic is currently accepting new patients.

Advanced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
Dr. Michael A. Stipanov
Hematology Oncology | Hematology | Oncology
Advanced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
Dr. Michael A. Stipanov
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

1750 Cedar Ln, Suite 200, 
Tullahoma, TN 
 (51.2 miles away)
615-333-2481
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Stipanov is a Hematologist Oncology specialist and a Hematologist in Tullahoma, Tennessee. Dr. Stipanov is rated as a Distinguished provider by MediFind in the treatment of Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency. His top areas of expertise are Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Dehydration. Dr. Stipanov is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Berdeja's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 30 Advanced Conditions
View All 41 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile